Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study.
- Registration Number
- NCT02248792
- Lead Sponsor
- Narayana Medical College & Hospital
- Brief Summary
Methotrexate (MTX) is considered the 'gold-standard' drug for the treatment of severe psoriasis. Health-related quality of life (HRQOL) is impaired in patients with psoriasis, more so if disease is severe.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Age range 18 to 65 years Both sexes Severe plaque-type psoriasis (BSA >10% or PASI >12) -
Read More
Exclusion Criteria
Pregnancy Lactation Malignancy or immunosuppression including HIV Liver disease Renal disease Non compliant Psychiatric illness Hypersensitivity to methotrexate in the past
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Group A Methotrexate Methotrexate 10mg orally once weekly Group B Methotrexate Methotrexate 25mg orally once weekly
- Primary Outcome Measures
Name Time Method Improvement in health related quality of life 12 weeks
- Secondary Outcome Measures
Name Time Method comparison of improvement in health related quality of life between Group A and Group B 12 weeks
Trial Locations
- Locations (1)
Narayana Med College and Hospital
🇮🇳Nellore, AP, India